ArticleDrug design, development and therapy2025
The Follicular Output Rate was Improved with 3-Day Letrozole Administration Compared with 5-Day Letrozole Administration Under Progestin-Primed Ovarian Stimulation.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letrozole Co-Administration in Progestin-Primed Ovarian Stimulation (PPOS) Protocols for Patients Undergoing In Vitro Fertilization: A Systematic Review.Journal of clinical medicine · 2026Review
- Building a predictive model for pregnancy outcomes in ART patients based on AMH, FORT, HCG day EMT, and clinical characteristics.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Progestin-primed ovarian stimulation (PPOS) has been widely employed in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. In recent years, letrozole (LE) combined with medroxyprogesterone acetate (MPA) has been used in this protocol to enhance ovarian response. This study compared the effects of a 5-day regimen with those of a 3-day regimen of letrozole within PPOS, focused on the follicular output rate (FORT) and blastocyst formation rates. Patients and Methods: From January 2017 to January 2020, 1,754 infertility patients who received PPOS protocol were divided into two groups: 577 patients received 2.5 mg/day LE for 5 days (LE 5-day), and 1177 patients received the same dose of LE for 3 days (LE 3-day). Propensity score matching (1:1) balanced confounders, yielding 489 patients per group. The primary outcoms was the FORT. The rate of blastocyst formation was evaluated as the secondary outcome. A multivariable logistic regression analysis was performed to compare the disparity in the FORT between the two groups. Results: After matching, the number of oocytes retrieved, number of mature oocytes, number of blastocysts, blastocyst formation rates, FORT, and clinical pregnancy rates were more favourable in the LE 3-day group than in the LE 5-day group (P < 0.05). In the multivariable linear regression model, after making adjustments for factors such as age, anti-Müllerian hormone (AMH), antral follicle count (AFC), body mass index (BMI), infertility type, and basal P, patients in the LE 3-day group exhibited an increase in the FOTR (β = 0.08, 95% confidence interval [CI] 0.02 to 0.14, P = 0.0082) and blastocyst formation rate (β = 0.23, 95% CI 0.17 to 0.29, P < 0.0001) compared to those in the LE 5-day group. Conclusion: Compared with LE administration for 5 days, LE administration for 3 days may increase the FORT and the rate of blastocyst formation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.